Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients

Yang, Cheng-WenCheng-WenYangLin, Mei-ChenMei-ChenLinShu, Kai-HsiangKai-HsiangShuTung, Kuei-TungKuei-TungTungTsai, Wan-ChuanWan-ChuanTsaiYang, Ju-YehJu-YehYangPai, Mei-FenMei-FenPaiWu, Hon-YenHon-YenWuChiu, Yen-LingYen-LingChiuPeng, Yu-SenYu-SenPengHsu, Shih-PingShih-PingHsuWang, Shi-HengShi-HengWangSZU-YU PAN2023-09-062023-09-06202302508095https://scholars.lib.ntu.edu.tw/handle/123456789/635105Although high-dose erythropoiesis-stimulating agent (ESA) has been shown to increase mortality risk and adverse cardiovascular events in hemodialysis patients, the safety of extremely low-dose ESA is unclear.enErythropoiesis-stimulating agent; Hemodialysis; Mortality[SDGs]SDG3Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patientsjournal article10.1159/000529806368542812-s2.0-85160874245https://api.elsevier.com/content/abstract/scopus_id/85160874245